

1 **Limit of detection in different matrices of nineteen commercially available rapid**  
2 **antigen tests for the detection of SARS-CoV-2**

3 Ana I. Cubas-Atienzar<sup>1\*</sup>, Konstantina Kontogianni<sup>1</sup>, Thomas Edwards<sup>1</sup>, Dominic

4 Wooding<sup>1</sup>, Kate Buist<sup>1</sup>, Caitlin R. Thompson<sup>1</sup>, Christopher T. Williams<sup>1</sup>, Edward I

5 Patterson<sup>2,3</sup>, Grant Hughes<sup>2</sup>, Lisa Baldwin<sup>1</sup>, Camille Escadafal<sup>4</sup>, Jilian A. Sacks<sup>4</sup>, Emily

6 R. Adams<sup>1</sup>

7 <sup>1</sup> Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, L3  
8 5QA, UK

9 <sup>2</sup> Liverpool School of Tropical Medicine, Departments of Vector Biology and Tropical  
10 Disease Biology, Centre for Neglected Tropical Diseases, Liverpool, L3 5QA, UK

11 <sup>3</sup> Brock University, Department of Biological Sciences, St. Catharines, L2S 3A1, Canada

12 <sup>4</sup> FIND, Foundation for Innovative New Diagnostics, Geneva, Switzerland

13

14

15

16 \* Address correspondence to Ana I Cubas Atienzar: [ana.cubasatienzar@lstmed.ac.uk](mailto:ana.cubasatienzar@lstmed.ac.uk)

17 **Keywords:** rapid diagnostic test (RDT); antigen detection; COVID-19; SARS-CoV-2;  
18 matrices; limit of detection (LOD)

19

## 20 **Abstract**

21 In the context of the coronavirus disease 2019 (COVID-19) pandemic there has been an  
22 increase of the use of antigen-detection rapid diagnostic tests (Ag-RDT). The performance of  
23 Ag-RDT vary greatly between manufacturers and evaluating their analytical limit of detection  
24 (LOD) has become high priority. Here we describe a manufacturer-independent evaluation of  
25 the LOD of 19 marketed Ag-RDT using live SARS-CoV-2 spiked in different matrices: direct  
26 culture supernatant, a dry swab, and a swab in Amies. Additionally, the LOD using dry swab  
27 was investigated after 7 days' storage at -80°C of the SARS-CoV-2 serial dilutions. An LOD of  $\approx$   
28  $5.0 \times 10^2$  pfu/ml ( $1.0 \times 10^6$  genome copies/ml) in culture media is defined as acceptable by the  
29 World Health Organization. Fourteen of nineteen Ag-RDTs (ActiveXpress, Espline, Excalibur,  
30 Innova, Joysbio, Mologic, NowCheck, Orient, PanBio, RespiStrip, Roche, Standard-F, Standard-  
31 Q and Sure-Status) exceeded this performance criteria using direct culture supernatant applied  
32 to the Ag-RDT. Six Ag-RDT were not compatible with Amies media and a decreased sensitivity  
33 of 2 to 20-fold was observed for eleven tests on the stored dilutions at -80°C for 7 days. Here,  
34 we provide analytical sensitivity data to guide appropriate test and sample type selection for use  
35 and for future Ag-RDT evaluations.

36  
37

38

## 39 **Introduction**

40 During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic,  
41 reverse transcription polymerase chain reaction (RT-PCR) has become the gold standard for  
42 diagnosis of acute infection<sup>1</sup>. However, RT-PCR technologies have several limitations: they are  
43 not deployed easily, require significant laboratory infrastructure, reagents, and skilled staff, and  
44 during this pandemic shortages in global supply have presented challenges<sup>2-4</sup>. In addition, the  
45 turnaround time from sample collection to result can be up to 72 hours compromising the  
46 effectiveness of triage, isolation, and contact tracing strategies<sup>5,6</sup>. In comparison, rapid  
47 diagnostic tests (RDTs) based on antigen detection (Ag-RDT) can determine the presence of  
48 the virus in a clinical sample on site in less than 30 minutes without the need for a laboratory.  
49 Ag-RDTs are faster, cheaper and can be available at the point-of-care (POC), which is  
50 especially important for implementation in community and low-resource settings, where limited  
51 laboratories and trained staff are available, and there may be suboptimal cold chain capacity to  
52 ensure appropriate conditions for more complex testing<sup>7-9</sup>. Furthermore, their use could also  
53 enable rapid isolation of cases and their contacts.

54 Ag-RDTs are less sensitive than RT-PCR, but clinical evaluation data is emerging that  
55 demonstrates Ag-RDTs are accurate at detecting the vast majority of individuals with a high-  
56 viral load (cycle threshold (Ct) on RT-PCR  $\leq 25.0$  or  $>10^6$  genomic virus copies/ml)<sup>7,10-16</sup>. In  
57 addition, in outbreak scenarios, a diagnostic test with lower sensitivity but a fast result enables  
58 quick interventions such as self-isolation and isolating contacts of cases<sup>17</sup>. Implementation of  
59 Ag-RDTs into testing algorithms would allow rapid detection and isolation of new cases and  
60 thereby support the test, trace and isolate strategy, aiming to stop transmission chains and  
61 reduce the impact of COVID-19.

62 Ag-RDTs have been recently used for screening asymptomatic people in high prevalence areas  
63 and frontline workers to quickly identify persons with a SARS-CoV-2 infection to adapt infection  
64 prevention and control measures, thus preventing transmission in the community<sup>18-20</sup>. A mass

65 testing program screening asymptomatic people in Slovakia using Ag-RDTs was shown to  
66 reduce the prevalence of SARS-CoV-2 infections by >50% within two weeks<sup>18</sup>.  
67 Despite the increased adoption of Ag-RDTs as an alternative of RT-PCR, independent  
68 analytical sensitivity data is currently lacking for many rapid antigen tests. Evaluation of Ag-  
69 RDTs using spiked samples in the laboratory before proceeding on clinical specimens is of  
70 paramount importance because the sensitivity of Ag-RDTs is highly variable depending on the  
71 manufacturer, ranging 0%-95% in respiratory samples<sup>7,21-24</sup> .  
72 Here we describe a single-center, manufacturer-independent analytical validation of nineteen  
73 commercially available Ag-RDTs. The aims of the study were to assess the limit of detection  
74 (LOD) using viral culture in different sample matrices: direct culture supernatant, dry swab and  
75 swabs in Amies. The effect on the LOD of one freeze-thaw cycle following storage at -80°C was  
76 also explored; demonstration of adequate performance using this sample type could support  
77 future rapid evaluation of Ag-RDTs with stored material.

## 78 **Results**

### 79 **LOD using different matrices**

80 The LOD was evaluated in three matrices: direct culture supernatant, dry swab and swab in  
81 Amies. Direct viral culture supernatant was used as it is the standardized protocol for the  
82 evaluation of LOD in Ag-RDTs<sup>25</sup>. Dry swab matrix using the proprietary swab kit was selected to  
83 evaluate the LOD in the sample type as defined in the instructions for use (IFU). Finally, swab in  
84 Amies was used to assess the use of the same swab used for RT-PCR as a sample type for Ag-  
85 RDTs.

86 A predefined performance criterion of an analytical LOD of  $\leq 5.0 \times 10^2$  plaque forming units  
87 (pfu)/ml ( $\approx 10^6$  genome copy numbers (gcn)/ml) using direct culture supernatant was selected  
88 based on current WHO and national standards<sup>25,26</sup>. Fourteen of nineteen Ag-RDTs evaluated in  
89 this study had an LOD of  $\leq 5.0 \times 10^2$  pfu/ml (ActiveXpress, Espline, Excalibur, Innova, Joysbio,

90 Mologic, NowCheck, Orient, PanBio, RespiStrip, Roche, Standard-F, Standard-Q and Sure-  
91 Status) using direct culture supernatant and the remaining had an LOD of  $1.0-5.0 \times 10^3$  pfu/ml  
92 (Biocredit, Genedia, iChroma and Wondfo) (Figure 1). Espline, iChroma, Innova Panbio and  
93 Roche had the lowest LOD using direct culture supernatant reaching  $0.5-1.0 \times 10^2$  pfu/ml,  
94 followed by ActiveXpress, Excalibur, Mologic, Orient, Standard-Q and Sure-Status and with an  
95 LOD of  $2.5 \times 10^2$  pfu/ml. Biocredit, Genedia, Respi-Strip, Standard-F and Wondfo and were the  
96 least sensitive with an LOD of  $0.5-5.0 \times 10^3$  pfu/ml. See Figure 1 and Supplementary materials  
97 for detailed LODs on all Ag-RDTs.

98 The LOD using dry swab was poorer in all tests when compared to direct culture supernatant  
99 with the exception of Mologic, where the LOD was the same using direct culture supernatant  
100 and dry swab. The LOD using dry swab was  $\leq 5.0 \times 10^2$  pfu/ml only in four Ag-RDT (Espline,  
101 Mologic, Roche and Sure-Status),  $1.0-5.0 \times 10^3$  pfu/ml in seven (Bioeasy, Innova, NowCheck,  
102 Orient, Panbio, Respi-Strip and Standard-Q) and  $\geq 1.0 \times 10^4$  pfu/ml in seven (ActiveXpress,  
103 Biocredit, Genedia, iChroma, Joysbio, Standard-F and Wondfo). The least sensitive using dry  
104 swab matrix was Joysbio with an LOD of  $2.5 \times 10^5$  pfu/ml (Figure 1).

105 None of the Ag-RDTs evaluated specifically indicate compatibility with swabs in Amies media.  
106 However, four tests recommend the use of universal or viral transport media (UTM/VTM)  
107 (Biocredit, Respi-Strip, Roche and Wondfo), three tests do not recommend the use of UTM/VTM  
108 (NowCheck, Standard-F and Standard-Q), and the remaining kits do not mention the use of any  
109 transport media. Six Ag-RDTs (Excalibur, Joysbio, NowCheck, Orient, Sure-Status and Wondfo)  
110 were found to be incompatible with the Amies media, as these showed a positive test line with  
111 the negative control sample. Of these, Wondfo is the only kit which recommends the use of  
112 transport media. LODs using swabs in Amies media was poorer than using dry swabs except in  
113 two test where the LOD was the same as with the dry swabs (PanBio and Standard-Q).

114 **Volume of liquid recovered by swabs**

115 We investigated whether the absorbance of the proprietary swabs provided with the Ag-RDT  
116 kits affected the LOD compared with direct culture supernatant i.e. if a less absorbent swab  
117 resulted in a poorer LOD in dry swab compared with the LOD obtained in direct culture  
118 supernatant for the same test. To test this hypothesis a Spearman's correlation coefficient was  
119 performed comparing direct culture supernatant and dry swab matrices from the same Ag-RDT.  
120 The volume recovered by swabs per tests are shown in supplementary materials. Spearman's  
121 correlation coefficient did not show any statistically significant correlation between the LOD and  
122 the volume recovered by swabs ( $P=0.421$ ,  $\rho=-0.50$ ), volume of extraction buffer ( $P=0.483$ ,  $\rho=-$   
123  $0.011$ ) and dilution factor (calculated by considering the volume recovered by swabs and  
124 volume of extraction buffer) ( $P=0.460$ ,  $\rho=-0.025$ ).

### 125 **LOD one freeze-thaw cycle after 7 days at $-80^{\circ}\text{C}$**

126 Ag-RDTs are intended to be POC tests and thus the majority are recommended for use with  
127 freshly collected specimens. To validate test performance, use of stored material is much  
128 easier. Therefore, we performed this experiment to understand whether LOD is impacted  
129 following sample storage. The LOD of each of the tests using SARS-CoV-2 serial dilutions after  
130 7 days storage at  $-80^{\circ}\text{C}$  and one freeze-thaw cycle is shown in Table 2.

131 The LOD for 6 tests (ActiveXpress, Bioeasy, iChroma, NowCheck, RespiStrip and Wondfo) was  
132 equivalent using stored, frozen viral dilutions compared to fresh preparations. Three tests  
133 showed increased sensitivity (lower LOD by 2 to 5-fold) (Joysbio, PanBio and Standard-Q), and  
134 eleven showed poorer performance with a higher LOD of 2-fold (Biocredit, Espline, Roche and  
135 Sure-Status), 4-5 (Excalibur, Mologic and Orient), ten (Innova) and twenty (Genedia and  
136 Standard-F).

### 137 **Discussion**

138 Here, we present the analytical performance of nineteen antigen rapid tests, which are currently  
139 on the market and in use in multiple countries. Analytical LODs are a useful proxy of clinical

140 sensitivity, and the most standardized way to evaluate multiple antigen tests head-to-head, as  
141 each test requires a separate swab from patients. An approximate LOD of  $\leq 5.0 \times 10^2$  pfu/ml ( $\approx$   
142  $1.0 \times 10^6$  copies/ml) calculated using direct culture supernatant, has been proposed as the  
143 minimal analytical sensitivity by the WHO and the Department of Health and Social Care  
144 (DHSC, U.K.)<sup>25,26</sup>. Fourteen of the nineteen marketed Ag-RDTs evaluated in this study fulfill this  
145 requirement (ActiveXpress, Bioeasy, Espline, Innova, Mologic, NowCheck, PanBio, Excalibur,  
146 RespiStrip, Joysbio, Roche, Standard-F, Standard-Q, Sure-Status and Orient).  
147 Evaluation of the LOD using the kit-specific swabs immersed in the viral culture dilutions offers a  
148 more representative comparison to the level of sensitivity for clinical samples than using direct  
149 viral culture. Only four of the nineteen tests detected samples with concentrations  $\leq 5.0 \times 10^2$   
150 pfu/ml ( $\approx 1.0 \times 10^6$  gcn/ml) when using the dry swabs (Mologic, Espline, Roche, Sure-Status)  
151 and none of the tests met that LOD target when using swabs in Amies, like due to the dilution  
152 factor with the addition of 1 ml Amies buffer as well as potential chemical interactions between  
153 the media and the kit-specific buffers.  
154 The more absorbent swabs will absorb more viral material, and so we investigated if the volume  
155 retained by the swab had any bearing on the LOD of each test when compared with the LOD  
156 achieved with direct culture supernatant. We took into account the volume recovered from the  
157 swab and the volume of proprietary buffer provided, but no correlation was found, this suggests  
158 that other factors may reduce the sensitivity when using swabs such as differences in the  
159 formulation of the proprietary buffers. A reduction in sensitivity using clinical samples may be  
160 observed compared to swabs in viral culture, as clinical samples are more viscous than culture  
161 media, potentially resulting in less viral material being absorbed onto the swab. The efficiency of  
162 the recovery is also likely to be increased by the centrifugation method used in our protocol.  
163 We also evaluated the LOD and compatibility of the Ag-RDTs using a swab placed in Amies  
164 media, as these are routinely used to collect upper-respiratory samples in SARS-CoV-2  
165 suspected individuals for diagnosis using RT-PCR<sup>27,28</sup>. If the same swab proves to be suitable

166 for both RT-PCR and rapid antigen testing, one swab can be used for both tests as part of a  
167 serial algorithm. As well, the frozen leftover Amies media from RT-PCR testing could be used  
168 for future Ag-RDT evaluations. Either approach could simplify clinical and/or evaluation  
169 workflows. None of the Ag-RDT manufacturers specifically recommend the use of Amies media,  
170 and we demonstrated here that this 'off-label' sample preparation should be used with caution:  
171 six tests had false positive results (Espline, Excalibur, Joysbio, Sure-Status and Orient) and  
172 sensitivity was also reduced due to the additional volume of Amies.

173 The effect of storage at -80°C and one freeze-thaw cycle was evaluated, with eleven Ag-RDTs  
174 showing a loss of sensitivity by up to twenty-fold. A small decrease in sensitivity has been  
175 reported in in SARS-CoV-2 RT-PCR testing (<1 RT-PCR cycle threshold) after one and two  
176 freeze-thaw cycles<sup>29</sup> but there are no studies so far that have reported the effect of freeze-thaw  
177 on antigen detection. Results here highlight that the use of frozen material with Ag-RDTs should  
178 be performed with caution. The fact that three tests showed two-to-five-fold better sensitivity  
179 after an additional freeze thaw-cycle could not be explained in here, a further investigation is  
180 required with a larger sample size to rule out whether this phenomenon was within the margin of  
181 error of the experiment.

182 Three out of nineteen Ag-RDTs (Bioeasy, iChroma and Standard-F) rely on detection of a  
183 fluorescent signal using a reader. Though this may enable quantitative detection and potentially  
184 more consistent result interpretation, we did not find any improved sensitivity for this test format.  
185 Furthermore, Ag-RDTs that rely on a device may limit testing throughput if only one test can be  
186 read at a time. The reader also presents additional costs, as well as potential technical and  
187 maintenance issues which can be a barrier to implementation.

188 This analytical study has some limitations, as only a single isolate  
189 (REMRQ0001/Human/2020/Liverpool) was used to assess the LODs but our results are  
190 consistent with other recently-published analyses<sup>30,31</sup>. To the authors knowledge, all 19 tests  
191 evaluated here detect the nucleoprotein, presumably chosen for abundance and relative low



192 mutation rate and therefore hypothesized to pick up all currently known variants<sup>32,33</sup>. Another  
193 limitation is that only one lot per kit was evaluated.

194 There is a growing number of studies suggesting that although antigen detection is less  
195 analytically sensitive than nucleic acid amplification techniques, it may strongly correlate with  
196 culturable virus, which may be a proxy for transmissibility. Hence Ag-RDTs could be informative  
197 for test, trace, isolate processes for the most infectious individuals<sup>10-15</sup>. Viral loads have been  
198 estimated to range from  $10^8$  to  $10^{11}$  gcn/ml in the most infectious patients<sup>34-36</sup>. The majority of  
199 Ag-RDTs evaluated here have an LOD predicted to successfully diagnose infected individuals  
200 with higher viral loads in this range across all matrices, except Joysbio that had an LOD of  $5.4 \times$   
201  $10^8$  gcn/ml in dry swab. Further, Biocredit, iChroma, Standard-F and Genedia tests had LOD  
202 greater than  $1.0 \times 10^8$  gcn/ml when using swabs placed in Amies and

203 In conclusion, the most sensitive tests with an  $\text{LOD} \leq 5.0 \times 10^2$  pfu/ml ( $\approx 1.2 \times 10^6$  gcn/ml) on dry  
204 swabs and direct culture supernatant were Espline, Mologic, Sure-Status and Roche and the  
205 least sensitive on all matrices were Biocredit, iChroma, Standard-F and Genedia. The  
206 differences of LODs found here between tests and/or matrices ranged between 2-3 logs (i.e.  
207 100-1,000 fold). Some tests showed impaired performance when using freeze-thaw material  
208 and/or Amies media. These findings highlight the importance of understanding assay specific  
209 performances and the need to select the appropriate sample matrix and the right test for each  
210 intended use, particularly for laboratories and evaluation programs that seek a rapid validation  
211 of Ag-RDT using frozen stored samples and 'off-label' specimen preparations. The LODs  
212 obtained in this comprehensive assessment of analytical sensitivity are consistent with rapidly  
213 emerging clinical performance data<sup>9,11,37</sup> demonstrating the high clinical accuracy of Ag-RDTs  
214 for rapid detection of individuals with high viral loads, which can be very impactful for initiation of  
215 isolation and tracing measures.

216

## 217 **Methods**

### 218 **Evaluated Ag-RDTs**

219 Nineteen Ag-RDT based on lateral flow principle were evaluated in this study (Table 1): (1)  
220 ActivXpress+ COVID-19 Ag Complete Kit (Edinburgh Genetics Ltd), referred to as  
221 ActivXpress+, (2) Biocredit COVID-19 Ag (Rapidgen Inc.), referred to as Biocredit, (3) Bioeasy  
222 2019-nCoV Ag (Shenzhen Bioeasy Biotechnology), referred to as Bioeasy, (4) Espline® SARS-  
223 CoV-2 (Fujirebio Diagnostics Inc.), referred to as Espline, (5) Genedia W COVID-19 Ag (Green  
224 Cross Medical Science), referred to as Genedia, (6) iChroma COVID-19 Ag Test (Boditech  
225 Medical Inc.), referred to as iChroma, (7) Innova SARS-CoV-2 Antigen Rapid (Innova Medical  
226 Group Ltd.), referred to as Innova, (8) Mologic COVID-19 Ag Test device (Mologic Ltd), referred  
227 to as Mologic, (9) NowCheck COVID-19 Ag test (Bionote Inc.), referred to as NowCheck, (10)  
228 Panbio™ COVID-19 Ag Rapid Test (Abbott Rapid Diagnostics), referred to as Panbio, (11)  
229 Rapid SARS-CoV-2 Antigen test card (Excalibur Healthcare Services), referred to as Excalibur,  
230 (12) Respi-Strip COVID-19 Ag (Coris Bioconcept), referred to as Respi-Strip, (13) SARS-CoV-2  
231 Antigen Rapid Test Kit (Joysbio Biotechnology Ltd.), referred to as Joysbio, (14) SARS-CoV-2  
232 Rapid Antigen Test (co-developed by SD Biosensor Inc and Roche Diagnostics, distributed by  
233 Roche Diagnostics), referred to as Roche, (15) Standard-F COVID-19 Ag FIA (SD Biosensor  
234 Inc), referred to as Standard-F, (16) Standard-Q COVID-19 (SD Biosensor Inc), referred to as  
235 Standard-Q, (17) Sure Status COVID-19 Antigen Card Test (Premier Medical Corporation),  
236 referred to as Sure-Status, (18) Coronavirus Ag Rapid Test (Zhejiang Orient Gene Biotech Ltd.),  
237 referred to as Orient, (19) Wondfo 2019-nCoV Antigen Test (Guangzhou Wondfo Biotech Co.),  
238 referred to as Wondfo. The selection of the Ag-RDT was based on expression of interest via the  
239 Infection Innovation Consortium (iiCON) and Foundation of New Diagnostics (FIND).  
240 Companies had no involvement in the design or reporting of the study.

### 241 **SARS-CoV-2 serial dilutions and quantification of copy numbers**

242 The SARS-CoV-2 isolate REMRQ0001/Human/2020/Liverpool was propagated in Vero E6 cells  
243 (C1008; African green monkey kidney cells), maintained in DMEM with 2% fetal bovine serum  
244 (FBS) and 0.05 mg/ml gentamycin. Ten-fold serial dilutions of SARS-CoV-2 stock were made  
245 starting from  $1.0 \times 10^6$  pfu/ml to  $1.0 \times 10^2$  pfu/ml using culture media as a diluent (DMEM with  
246 2% FBS % and 0.05 mg/ml gentamycin). Two-fold dilutions were made below the ten-fold LOD  
247 dilution to refine the LOD. For quantification, viral RNA was extracted using QIAmp Viral RNA  
248 mini kit (Qiagen, Germany) according to the manufacturer's instructions. The genome copies/ml  
249 (gcn/ml) were calculated using the COVID-19 Genesig RT-qPCR kit (PrimerDesign, UK). RT-  
250 qPCR testing was carried out using the Rotor-Gene Q (Qiagen, Germany), with a ten-fold serial  
251 dilution of using quantified specific in vitro-transcribed RNA<sup>38</sup>. A total of five replicates were  
252 tested for each standard curve point and extracted RNA from each culture dilution was tested in  
253 triplicate, and the gcn/ml was calculated from the mean Ct value of these replicates.

#### 254 **Preparation of SARS-CoV-2 sample matrices and LOD testing protocol**

255 Three types of sample matrices were tested 1) direct viral culture supernatant, 2) spiked dry  
256 swabs and 3) spiked wet swabs in Amies media.

257 For the direct viral culture matrix, a specific volume of the serial dilutions was added directly to  
258 the extraction buffers at a 1:10 ratio except for Respi-Strip which was added at 1:1 ratio with the  
259 extraction buffer following the IFU.

260 For dry swab testing, the proprietary nasopharyngeal (NP) or nasal (N) swabs included in each  
261 individual kit was used except for Respi-Strip, which does not include swabs, and the  
262 recommended Eswab (Copan, Italy) was used instead. To prepare the dry swab matrix, the  
263 swab was soaked in 1 ml of the virus culture dilution series for 6-8 seconds, followed by  
264 immersion in the prescribed amount of proprietary reaction buffer solution.

265 For the preparation of spiked wet swabs, Eswab in Amies media (Copan, Italy) was used across  
266 all tests. The swab was first immersed in the serial viral dilutions for 6-8 seconds, then placed  
267 into the Amies media to mimic the sample collection stage. Ag-RDTs were evaluated by then

268 immersing the same swab into the extraction buffer, except for test Respi-Strip where 100µl of  
269 the Amies was mixed at 1:1 with the extraction buffer following its IFU.

270 For all Ag-RDTs and matrices, the sample volumes applied, and procedures were performed as  
271 specified in the test specific IFUs.

272 The LOD was defined as the lowest dilution at which all three replicates were positive. Every  
273 dilution was tested in triplicate and non-spiked culture media and Amies were used as negative  
274 controls. Results were interpreted by two operators, each blinded to the result of the other. If a  
275 discrepant result was obtained, a third operator read any discrepant tests for a 2/3 result.

#### 276 **Volume of liquid recovered by swabs**

277 We investigated the effect of the absorbance of the proprietary swabs provided with the Ag-RDT  
278 kit in the LOD using dry swab, i.e. if a less absorbent swab resulted in a poorer LOD on dry  
279 swab compared with direct culture supernatant. To compare the effectiveness of each NP and N  
280 swab to recover sample, the amount of liquid absorbed by the swabs was measured. Five  
281 replicates of each swab brand were immersed in culture media for 6-8 seconds, then taped on  
282 the inside of a 50ml centrifuge tube. These were then centrifuged for 5 minutes at 1000g and  
283 the amount of liquid released was measured using a micropipette. The dilution factor of each  
284 test type was calculated taking into account the volume recovered by swab and volume of  
285 proprietary buffer in which the swab was immersed.

286 The degree of correlation of LOD by swabs with the volume recovered by swab type, volume of  
287 proprietary buffer and dilution factor were investigated by Spearman's correlation coefficient rho  
288 ( $\rho$ ). Statistical significance was set at  $P < 0.05$ .

#### 289 **LOD after 7 days at -80° C and one freeze-thaw cycle**

290 After performing the LOD experiments, the viral culture dilutions were stored at -80 °C for 7  
291 days and then the LOD experiments were performed again using the dry NP and N swabs. This  
292 would help to assess the use of stored clinical samples could be used to facilitate evaluation of  
293 Ag-RDTs.

294 **Data availability.** All data generated during this study is presented in an analysed format in this  
295 manuscript. Raw datasets are available from the corresponding author on reasonable request.

296 **Authors' contributions:** The study and design of the study was conceived by AICA, JS and  
297 ERA. Laboratory testing was performed by AICA, KK, TE, CW, DW, KB, CT. Data analysis and  
298 interpretation were conducted by AICA. The initial manuscript was prepared by AICA. All authors  
299 edited and approved the final manuscript.

300 **Sources of funding:** The study was supported by FIND. The funders of the study had no  
301 role in data collection and data analysis.

302 **Compelling Interest:** The authors have no conflicts of interest to declare.

303

304

305

306

307

## 308 References

- 309 1. Corman, V., Bleicker, T., Brünink, S. & Drosten, C. *Diagnostic detection of 2019-*  
310 *nCoV by real-time RT-PCR*. [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf)  
311 [source/coronaviruse/protocol-v2-1.pdf](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf) (2020).
- 312 2. Akst, J. RNA Extraction Kits for COVID-19 Tests Are in Short Supply in US. *The*  
313 *Scientist* [https://www.the-scientist.com/news-opinion/rna-extraction-kits-for-covid-](https://www.the-scientist.com/news-opinion/rna-extraction-kits-for-covid-19-tests-are-in-short-supply-in-us-67250)  
314 [19-tests-are-in-short-supply-in-us-67250](https://www.the-scientist.com/news-opinion/rna-extraction-kits-for-covid-19-tests-are-in-short-supply-in-us-67250) (2020).
- 315 3. Kuznia, R., Curt, D. & Griffin, D. Severe shortages of swabs and other supplies  
316 hamper coronavirus testing - CNN. *CNN US*  
317 [https://www.cnn.com/2020/03/18/us/coronavirus-testing-supply-shortages-](https://www.cnn.com/2020/03/18/us/coronavirus-testing-supply-shortages-invs/index.html)  
318 [invs/index.html](https://www.cnn.com/2020/03/18/us/coronavirus-testing-supply-shortages-invs/index.html).
- 319 4. Reagents hold up European COVID-19 tests. *C&EN Glob. Enterp.* (2020)  
320 doi:10.1021/cen-09813-buscon3.
- 321 5. Weekly statistics for NHS Test and Trace (England): 7 January to 13 January  
322 2021. *GOV.UK* (2021).
- 323 6. Kretzschmar, M. E. *et al.* Impact of delays on effectiveness of contact tracing  
324 strategies for COVID-19: a modelling study. *Lancet Public Heal.* (2020)  
325 doi:10.1016/S2468-2667(20)30157-2.
- 326 7. World Health Organization (WHO). Antigen-detection in the diagnosis of SARS-  
327 CoV-2 infection using rapid immunoassays. *Interim Guid.* (2020).
- 328 8. Adams, E. R. *et al.* Rapid development of COVID-19 rapid diagnostics for low  
329 resource settings: accelerating delivery through transparency, responsiveness,  
330 and open collaboration. *medRxiv* (2020) doi:10.1101/2020.04.29.20082099.
- 331 9. Krüger, L. J. *et al.* Evaluation of the accuracy, ease of use and limit of detection of  
332 novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2.  
333 *medRxiv* (2020).
- 334 10. Weiss, G. & Bellmann-Weiler, R. Rapid antigen testing and non-infectious  
335 shedding of SARS-Cov2. *Infection* (2021) doi:[https://doi.org/10.1007/s15010-020-](https://doi.org/10.1007/s15010-020-01570-w)  
336 [01570-w](https://doi.org/10.1007/s15010-020-01570-w).
- 337 11. Iglói, Z. *et al.* Clinical evaluation of the Roche/SD Biosensor rapid antigen test  
338 with symptomatic, non-hospitalized patients in a municipal health service drive-  
339 through testing site. *medRxiv* (2020).
- 340 12. Mina, M. J., Parker, R. & Larremore, D. B. Rethinking Covid-19 Test Sensitivity —  
341 A Strategy for Containment. *N. Engl. J. Med.* (2020) doi:10.1056/nejmp2025631.
- 342 13. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK.  
343 *Eur. Cent. Dis. Prev. Control.* (2020).
- 344 14. Pekosz, A. *et al.* Antigen-based testing but not real-time PCR correlates with  
345 SARS-CoV-2 virus culture. *medRxiv* (2020).
- 346 15. Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR  
347 cycle threshold values in cases of COVID-19, England, January to May 2020.  
348 *Eurosurveillance* (2020) doi:10.2807/1560-7917.ES.2020.25.32.2001483.
- 349 16. Abduljalil, J. M. Laboratory diagnosis of SARS-CoV-2: available approaches and  
350 limitations. *New Microbes and New Infections* (2020)  
351 doi:10.1016/j.nmni.2020.100713.
- 352 17. Bonačić Marinovic, A. A. *et al.* Speed versus coverage trade off in targeted

- 353 interventions during an outbreak. *Epidemics* (2014)  
354 doi:10.1016/j.epidem.2014.05.003.
- 355 18. Mahase, E. Covid-19: Mass testing in Slovakia may have helped cut infections.  
356 *BMJ* (2020) doi:10.1136/bmj.m4761.
- 357 19. Gill, M. & Gray, M. Mass testing for covid-19 in the UK. *The BMJ* (2020)  
358 doi:10.1136/bmj.m4436.
- 359 20. Wise, J. Covid-19: Government ramps up“Moonshot”mass testing. *BMJ* **371**,  
360 (2020).
- 361 21. Mak, G. C. *et al.* Evaluation of rapid antigen test for detection of SARS-CoV-2  
362 virus. *J. Clin. Virol.* (2020) doi:10.1016/j.jcv.2020.104500.
- 363 22. Nagura-Ikeda, M. *et al.* Clinical evaluation of self-collected saliva by quantitative  
364 reverse transcription-PCR (RT-qPCR), Direct RT-qPCR, reverse transcription-  
365 loop-mediated isothermal amplification, and a rapid antigen test to diagnose  
366 COVID-19. *J. Clin. Microbiol.* (2020) doi:10.1128/JCM.01438-20.
- 367 23. Scohy, A. *et al.* Low performance of rapid antigen detection test as frontline  
368 testing for COVID-19 diagnosis. *J. Clin. Virol.* (2020)  
369 doi:10.1016/j.jcv.2020.104455.
- 370 24. Weitzel, T. *et al.* Head-to-head comparison of four antigen-based rapid detection  
371 tests for the diagnosis of SARS-CoV-2 in respiratory samples. *bioRxiv* (2020)  
372 doi:10.1101/2020.05.27.119255.
- 373 25. gov.uk. Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-  
374 2 antigens (lateral flow devices).
- 375 26. (WHO), W. H. O. & R&D Blue Print, W. H. (HQ). Target product profiles for priority  
376 diagnostics to support response to the COVID-19 pandemic v.1.0. (2020).
- 377 27. Center of Disease Control and Prevention. Interim Guidelines for Collecting,  
378 Handling, and Testing Clinical Specimens for COVID-19. *May 22* (2020).
- 379 28. Federman, D. G. *et al.* SARS-CoV-2 detection in setting of viral swabs scarcity:  
380 Are mrsa swabs and viral swabs equivalent? *PLoS One* (2020)  
381 doi:10.1371/journal.pone.0237127.
- 382 29. Li, L. *et al.* Influence of Storage Conditions on SARS-CoV-2 Nucleic Acid  
383 Detection in Throat Swabs. *J. Infect. Dis.* (2020) doi:10.1093/infdis/jiaa272.
- 384 30. Corman, V. M. *et al.* Comparison of seven commercial SARS-CoV-2 rapid Point-  
385 of-Care Antigen tests. *medRxiv* (2020) doi:10.1101/2020.11.12.20230292.
- 386 31. Jääskeläinen, A. *et al.* Evaluation of three rapid lateral flow antigen detection tests  
387 for the diagnosis of SARS-CoV-2 infection. *medRxiv* (2021).
- 388 32. Bar-On, Y. M., Flamholz, A., Phillips, R. & Milo, R. Sars-cov-2 (Covid-19) by the  
389 numbers. *Elife* (2020) doi:10.7554/eLife.57309.
- 390 33. Dutta, N. K., Mazumdar, K. & Gordy, J. T. The Nucleocapsid Protein of SARS-  
391 CoV-2: a Target for Vaccine Development. *J. Virol.* (2020) doi:10.1128/jvi.00647-  
392 20.
- 393 34. Kawasuji, H. *et al.* Transmissibility of COVID-19 depends on the viral load around  
394 onset in adult and symptomatic patients. *PLoS One* (2020)  
395 doi:10.1371/journal.pone.0243597.
- 396 35. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected  
397 Patients. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMc2001737.
- 398 36. Walsh, K. A. *et al.* SARS-CoV-2 detection, viral load and infectivity over the

- 399 course of an infection. *Journal of Infection* (2020) doi:10.1016/j.jinf.2020.06.067.  
400 37. van der Moeren, N. *et al.* Performance evaluation of a SARS-COV-2 rapid  
401 antigen test: Test performance in the community in the Netherlands. *medRxiv*  
402 (2020) doi:10.1101/2020.10.19.20215202.  
403 38. Byrne, R. L. *et al.* Saliva offers a sensitive, specific and non-invasive alternative to  
404 upper respiratory swabs for SARS-CoV-2 diagnosis. *medRxiv* (2020)  
405 doi:10.1101/2020.07.09.20149534.  
406



407

408 List of tables

409 Table 1. Characteristics of the Ag-RDT tested

410 Table 2. LOD after one week -80°C storage and one freeze-thaw cycle

411 List of Figures

412 Figure 1. Heatmap of the LODs on all matrices.

413


414

415

**Table 1. Characteristics of the Ag-RDT tested.**

Test name in this study	Assay	Manufacturer/Distributor	Country	Recommended sample	Principle	Format	Minutes to result
ActiveXpress	ActivXpress+ COVID-19 Ag Complete Kit	Edinburgh Genetics Ltd	UK	NP/OP swab	Colloidal gold	Cassette	15-20
Biocredit	Biocredit COVID-19 Ag	Rapidgen Inc.	Rep. Korea	NP swab/UTM/VTM	Colloidal gold	Cassette	30
Bioeasy	Bioeasy 2019-nCoV Ag	Shenzhen Bioeasy Biotechnology	China	NP swab	Fluorescence	Cassette	10
Espline	ESPLINE® SARS-CoV-2	Fujirebio Diagnostics Inc.	Japan	NP swab	Colloidal gold	Cassette	30
Excalibur	Rapid SARS-CoV-2 Antigen test card	Boson Diagnostics/Excalibur Healthcare Services	UK	NP swab	Colloidal gold	Cassette	15
Genedia	GENEDIA W COVID-19 Ag	Green Cross Medical Science.	Rep. Korea	NP swab/Sputum	Colloidal gold	Cassette	5-10
iChroma	iChroma COVID-19 Ag Test	Boditech Medical Inc.	Rep. Korea	NP swab	Fluorescence	Cassette	12
Innova	Innova SARS-CoV-2 Antigen Rapid	Innova Medical Group Ltd.	UK	N/T swab	Colloidal gold	Cassette	15
Joysbio	SARS-CoV-2 Antigen Rapid Test Kit	Joysbio Biotechnology Ltd.	China	N swab	Colloidal gold	Cassette	15-20
Mologic	Mologic COVID-19 Ag Test device	Mologic Ltd.	UK	T/N/NT swab	Colloidal gold	Cassette	10
NowCheck	NowCheck COVID-19 Ag test	Bionote Inc./Mologic Ltd.	Rep. Korea	NP swab	Colloidal gold	Cassette	15-30
Orient	Coronavirus Ag Rapid Test	Zhejiang Orient Gene Biotech Ltd.	China	NP swab	Colloidal gold	Cassette	10-15
PanBio	Panbio™ COVID-19 Ag Rapid Test	Abbott Rapid Diagnostics	Rep. Korea	NP swab	Colloidal gold	Cassette	15
RespiStrip	Respi-Strip COVID-19 Ag	Coris Bioconcept	Belgium	NP wash/UTM/VTM	Colloidal gold	Dipstick	15-30
Roche	SARS-CoV-2 Rapid Antigen Test	SD Biosensor Inc./ Roche Diagnostics)	Switzerland	NP swab/VTM/UTM	Colloidal gold	Cassette	15-30
Standard-F	Standard F COVID-19 Ag FIA	SD Biosensor Inc.	Rep. Korea	NP swab	Fluorescence	Cassette	15-30
Standard-Q	Standard Q COVID-19	SD Biosensor Inc.	Rep. Korea	NP swab	Colloidal gold	Cassette	15
Sure-Status	Sure-Status COVID-19 Antigen Card Test	Premier Medical Corporation	India	NP swab	Colloidal gold	Cassette	15-20
Wondfo	Wondfo 2019-nCoV Antigen Test	Guangzhou Wondfo Biotech Co.	China	NP/OP swab/VTM	Colloidal gold	Cassette	10-15

Abbreviations: Rep.: Republic, OP: oropharyngeal, NP: nasopharyngeal, N: nasal, T: throat, NT: nasal-throat, UTM: universal transport media, VTM: viral transport media



**Figure 1. Heatmap of the LODs on all matrices. Ag-RDTs in direct culture matrix colored green fulfilled WHO criteria.**

**Note: no colored cells for direct culture indicates no Ag-RDT was tested with that matrix, no colored cells in swab in Amies swab means interference with that matrix, hence LOD is not available.**

**Table 2. LOD after one week -80°C storage and one freeze-thawed cycle**

<b>Test</b>	<b>LOD dry swab</b>	<b>LOD after -80°C storage</b>
ActiveXpress	1.0 x 10 <sup>4</sup>	1.0 x 10 <sup>4</sup>
Biocredit	5.0 x 10 <sup>4</sup>	1.0 x 10 <sup>5</sup>
Bioeasy	5.0 x 10 <sup>3</sup>	5.0 x 10 <sup>3</sup>
Espline	5.0 x 10 <sup>2</sup>	1.0 x 10 <sup>3</sup>
Genedia	2.5 x 10 <sup>4</sup>	5.0 x 10 <sup>5</sup>
IChroma	1.0 x 10 <sup>4</sup>	1.0 x 10 <sup>4</sup>
Innova	1.0 x 10 <sup>3</sup>	1.0 x 10 <sup>4</sup>
Mologic	2.5 x 10 <sup>2</sup>	1.0 x 10 <sup>3</sup>
NowCheck	5.0 x 10 <sup>3</sup>	5.0 x 10 <sup>3</sup>
PanBio	5.0 x 10 <sup>3</sup>	2.5 x 10 <sup>3</sup>
Excalibur	1.0 x 10 <sup>3</sup>	5.0 x 10 <sup>3</sup>
RespiStrip	5.0 x 10 <sup>3</sup>	5.0 x 10 <sup>3</sup>
Joysbio	2.5 x 10 <sup>5</sup>	1.0 x 10 <sup>5</sup>
Roche	5.0 x 10 <sup>2</sup>	1.0 x 10 <sup>3</sup>
Standard-F	2.5 x 10 <sup>4</sup>	5.0 x 10 <sup>5</sup>
Standard-Q	5.0 x 10 <sup>3</sup>	1.0 x 10 <sup>3</sup>
Sure-Status	5.0 x 10 <sup>2</sup>	1.0 x 10 <sup>3</sup>
Orient	2.5 x 10 <sup>3</sup>	1.0 x 10 <sup>4</sup>
Wondfo	2.5 x 10 <sup>3</sup>	2.5 x 10 <sup>3</sup>

